A Tribute to Pat Padgett. A Brave Oral Cancer Patient That Inspired Us to Develop PRV111.
Our clinical trial for oral cancer opened within 3 years from the passing of a friend and a trainer, Pat Padgett. Pat battled oral cancer and lost this battle at a young age.
Pat was the original patient who in part inspired us. Please see http://www.crossfitsouthie.com/tribute-pat-padgett-competitorwod/ .
When asked about Privo’s trial, Dr. Jason Sager, MD, an oncologist, and Pat’s friend said: “I am so happy that within a short timespan, Privo’s topical and local product is being studied. It might have saved Pat Padgett and has the potential to save many many others”.
Vitamin D Supplements Don’t Reduce Cancer Incidence, Trial Shows
A large body of epidemiology research had suggested that people with higher blood levels of vitamin D have a lower risk of cancer, said Barry Kramer, M.D., director of NCI’s Division of Cancer Prevention.
However, such studies can only highlight associations, not prove cause and effect, he added. “This is why it’s important to question intuitions and observational epidemiology studies, and fund large-scale trials,” Dr. Kramer continued; they can conclusively show whether a treatment—in this case, a dietary supplement—truly can help to prevent cancer.
Results from the trial called the Vitamin D and Omega-3 Trial (VITAL), were published November 10 in the New England Journal of Medicine (NEJM).
December 4, 2018, by NCI Staff
Credit: Northwestern Medicine
The drug tamoxifen can help prevent breast cancer in women at an increased risk of the disease. But many women who stand to benefit from do not take the drug—a pill—because of concerns about side effects, such as and .
To explore alternatives to oral tamoxifen that might have fewer side effects, researchers are testing a topical form of the drug in two clinical trials. These studies are evaluating a gel formulation of tamoxifen called (4-OHT) that women apply directly to the breasts.
The goal of this research is to find out if delivering a form of tamoxifen topically results in the same level of the drug in the breast but leads to lower levels of the drug in the blood and other parts of the body compared with oral delivery, according to Brandy Heckman-Stoddard, Ph.D., of NCI’s .
“With lower levels of the drug in the body, women would potentially have fewer side effects,” she added.
Testing a Topical Drug for Breast Cancer Prevention
Four years ago, Seema Khan, M.D., of Northwestern University Feinberg School of Medicine led in the lining of the breast duct—a condition known as (DCIS)—among women treated with the gel applied to the breast skin and women treated with oral tamoxifen. (In women with DCIS, the abnormal cells have not yet spread to other tissues in the breast.)
“We found a similar reduction in the growth of DCIS cells from both the gel and the pill form of the drug, and the concentrations [of tamoxifen] in the breasts of women who were treated with the gel were quite good,” said Dr. Khan, who is leading . 4-OHT has the feel and consistency of hand sanitizer gel, she noted.
Dr. Khan cautioned that those results need to be confirmed by the randomized placebo-controlled clinical trials now underway. She also noted that the 4-OHT gel is intended for use in a specific group of women.
“This approach is for healthy women who have an increased risk of breast cancer and for women with DCIS,” said Dr. Khan. “When the problem is confined to the breast, this approach would be appropriate.”
Using a topical drug would not be a viable approach once breast cancer cells have broken through the duct walls, because those cancer cells can go elsewhere in the body, she explained.
For women with DCIS, the topical application is “a local treatment for a local condition,” said Dr. Heckman-Stoddard.